Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

A synthetic hexapeptide that stimulates growth hormone secretion by mimicking ghrelin and binding to GHS receptors in the pituitary gland.

Quick Stats
Studies 702
Trials 0
Formula C46H56N12O6
Clear All
Utility 3
pubmed 1997

Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.

Villas-Boas Weffort. R F RF; Ramos-Dias. J C JC; Chipoch. C C; Lengyel. A M AM

The study shows that the peptide GHRP‑6 triggers a growth‑hormone (GH) surge in people with insulin‑dependent diabetes just as well as in healthy individuals. Adding the natural hormone GHRH on top of GHRP‑6 makes the GH spike even bigger, and this synergy works the same way in both groups.

Utility 3
pubmed 1996

Retrogradely labelled neurosecretory neurones of the rat hypothalamic arcuate nucleus express Fos protein following systemic injection of GH-releasing peptide-6.

Dickson. S L SL; Doutrelant-Viltart. O O; Dyball. R E RE; Leng. G G

The study shows that when you give GHRP‑6 to rats, it turns on a large share (about 70‑80%) of hypothalamic neurons that send signals out of the brain to release hormones. These activated cells are not the dopamine‑producing (TH) or beta‑endorphin cells, meaning GHRP‑6 mainly stimulates other hormone‑releasing neurons, likely the ones that trigger growth hormone release.

Utility 3
pubmed May 14, 1997

Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone.

Giustina. A A; Bonfanti. C C; Licini. M M; Ragni. G G; Stefana. B B

The study shows that hexarelin, a stronger version of GHRP-6, can make pituitary cells release growth hormone even when they don’t respond to the usual hormone (GHRH). This means hexarelin works through a different route, and it boosts GH in both normal rat pituitary cells and a tumor cell line that normally ignores GHRH.

Utility 3
pubmed 1997

Effects of growth hormone secretagogues in the transgenic growth-retarded (Tgr) rat.

Wells. T T; Flavell. D M DM; Wells. S E SE; Carmignac. D F DF; Robinson. I C IC

In a special strain of dwarf rats that lack normal pituitary growth hormone, the peptide GHRP‑6 still managed to trigger big spikes of GH and, when given continuously for a week, helped the animals grow. This shows that even when the body’s own GH production is impaired, GHRP‑6 can still boost GH release and promote growth.

Utility 3
pubmed 1995

Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action.

Fairhall. K M KM; Mynett. A A; Robinson. I C IC

The study shows that GHRP‑6 triggers a big jump in growth hormone (GH) when it reaches the brain, and this effect can be shut down by somatostatin, a hormone that normally blocks GH. Giving GHRP‑6 directly into the bloodstream needs a lot more of the peptide to get the same GH boost, meaning its main action is in the brain, not the pituitary.

Utility 3
pubmed 1996

Different growth hormone (GH) response to GH-releasing peptide and GH-releasing hormone in hyperthyroidism.

Ramos-Dias. J C JC; Pimentel-Filho. F F; Reis. A F AF; Lengyel. A M AM

People with an overactive thyroid (hyperthyroidism) don’t get a strong growth‑hormone boost from the usual hormone‑releasing drug (GHRH), but they do respond normally to the peptide GHRP‑6. This means GHRP‑6 can still trigger a good GH surge even when thyroid hormones are high.

Utility 3
pubmed Apr 1, 1996

GHRP6-stimulated hormone secretion in somatotrophs: involvement of intracellular and extracellular calcium sources.

Bresson-Bepoldin. L L; Dufy-Barbe. L L

GHRP‑6 makes the pituitary release growth hormone by first pulling calcium out of the cell’s internal stores and then letting calcium flow in from outside. Both steps matter – stopping the internal release cuts the hormone boost, and blocking the external entry cuts it by about half. The whole process also needs an active PKC enzyme; if PKC is blocked, GHRP‑6 stops working altogether.

Utility 3
pubmed Jul 18, 1995

Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

Patchett. A A AA; Nargund. R P RP; Tata. J R JR; Chen. M H MH; Barakat. K J KJ; Johnston. D B DB; Ch...

The study shows that the compound L-163,191 (also called MK-0677) is a very strong, oral drug that makes the body release growth hormone, working in a way that's almost identical to the peptide GHRP‑6. In animal tests it boosted GH at tiny doses and didn’t noticeably change other hormones except for a small rise in cortisol.

Utility 3
pubmed 1996

Identification of a new G-protein-linked receptor for growth hormone secretagogues.

Pong. S S SS; Chaung. L Y LY; Dean. D C DC; Nargund. R P RP; Patchett. A A AA; Smith. R G RG

Scientists discovered that GHRP‑6 and similar compounds attach to a special receptor in the pituitary gland that is different from the usual growth‑hormone‑releasing hormone (GHRH) receptor. This new receptor is a G‑protein‑coupled type, needs magnesium to work, and its binding strength matches how much growth hormone is released.

Utility 3
pubmed 1990

Oral activity of the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in rats, dogs and monkeys.

Walker. R F RF; Codd. E E EE; Barone. F C FC; Nelson. A H AH; Goodwin. T T; Campbell. S A SA

The study shows that GHRP‑6 can still make the body release growth hormone when you swallow it, but it works much less efficiently than when injected—about 1% as strong. Different animals need different amounts, with monkeys (a close model to humans) responding to much lower oral doses than rats or dogs.

Utility 3
pubmed Jan 1, 1993

Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6.

Peñalva. A A; Pombo. M M; Carballo. A A; Barreiro. J J; Casanueva. F F FF; Dieguez. C C

GHRP‑6 reliably spikes growth hormone in adults and kids, and it works the same way in men, women, and across the menstrual cycle. Blocking alpha‑1 receptors with prazosin makes the GH surge even bigger, while beta‑blockers (propranolol) and alpha‑2 agonists (clonidine) don’t change the response.

Utility 3
pubmed Oct 1, 1995

Growth hormone secretagogues. Clinical experience and therapeutic potential.

Laron. Z Z

The abstract says that GHRP‑6 and similar short peptides can strongly stimulate the body’s own growth hormone (GH) and IGF‑1, especially when used together with a GH‑releasing hormone (GHRH). They work whether you inject them, take them by mouth, or give them under the skin, and they have been shown to cause the same metabolic changes as GH, like faster growth in kids, with few reported side effects.

Utility 3
pubmed 1997

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

Chapman. I M IM; Pescovitz. O H OH; Murphy. G G; Treep. T T; Cerchio. K A KA; Krupa. D D; Gertz. B B...

A short 4‑day study gave nine young men who lack growth hormone (GH) either 10 mg or 50 mg of the oral GH‑releasing compound MK‑677 (also called Ibutamoren). Both doses raised their blood GH and IGF‑1 levels by roughly 50‑80% and also increased a binding protein (IGFBP‑3). The drug was well tolerated, but it also pushed fasting and post‑meal insulin and glucose up, so longer‑term safety isn’t known.

Utility 3
pubmed 1995

Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children.

Mericq. V V; Cassorla. F F; Garcia. H H; Avila. A A; Bowers. C Y CY; Merriam. G R GR

In kids who can’t make enough growth hormone, a peptide called GHRP‑1 (a close cousin of GHRP‑6) sparked a hormone rise in about 60% of them, similar to the classic hormone‑releasing drug GHRH. When the two were taken together, the hormone surge was much bigger than either alone, showing a strong synergy. The spikes were smaller than those seen in healthy people, but the study proves that these secretagogue peptides can still work even when the body’s own GHRH system is weak.

Utility 3
pubmed Jul 1, 1994

Constitutive growth hormone secretion in sheep after hypothalamopituitary disconnection and the direct in vivo pituitary effect of growth hormone releasing peptide 6.

Fletcher. T P TP; Thomas. G B GB; Willoughby. J O JO; Clarke. I J IJ

In sheep that had their brain‑pituitary connection cut, the normal burst‑like release of growth hormone (GH) stopped, but a low steady level kept flowing. Giving the peptide GHRP‑6 still raised GH levels, proving it can act directly on the pituitary, though the boost was smaller than that from a classic growth‑hormone‑releasing factor (GRF).

Utility 3
pubmed Sep 10, 1998

Novel orally active growth hormone secretagogues.

Hansen. T K TK; Ankersen. M M; Hansen. B S BS; Raun. K K; Nielsen. K K KK; Lau. J J; Peschke. B B; L...

Scientists have created a new, smaller class of compounds that can trigger the body to release growth hormone and can be taken by mouth. In animal tests (pigs and dogs) these molecules showed decent oral absorption (10‑55%) and kept their ability to boost growth hormone, with the most potent one working at a dose of about 30 nmol per kilogram of body weight.

Utility 3
pubmed 1993

Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-induced GH secretion in the rat.

Mallo. F F; Alvarez. C V CV; Benitez. L L; Burguera. B B; Coya. R R; Casanueva. F F FF; Dieguez. C C

In rats, the peptide GHRP-6 reliably triggers a spike in growth hormone (GH) even when the brain's usual control centers are removed, showing it works directly on the pituitary gland. The hormone boost is stronger in animals given estrogen or testosterone, but weaker when cortisol (from dexamethasone), high blood fats, or bombesin are present. Repeated GHRP-6 dosing for two weeks doesn’t change the acute GH response.

Utility 3
pubmed 1994

Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging.

Ghigo. E E; Arvat. E E; Rizzi. G G; Goffi. S S; Grottoli. S S; Mucci. M M; Boghen. M F MF; Camanni....

A small study in older women showed that taking the peptide GHRP‑6 by mouth (about 300 µg per kg of body weight) caused a clear rise in growth hormone, even more than an IV dose of GHRH. After four days of taking the peptide twice daily, the hormone‑boosting effect was still there and even trended upward, though the longer‑term growth factor IGF‑1 didn’t change noticeably in that short period.

Utility 3
pubmed 1994

Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles.

Jacks. T T; Hickey. G G; Judith. F F; Taylor. J J; Chen. H H; Krupa. D D; Feeney. W W; Schoen. W W;...

In dogs, a new compound called L-692,585 caused a big jump in growth hormone (GH) levels—up to 21 times higher than a salty control—and was 2‑2.5 times more powerful than the well‑known peptide GHRP‑6. The GH spike happened within 5‑15 minutes and fell back to normal by about 90 minutes. Giving the drug every day for two weeks kept boosting GH without any sign of the body getting used to it. This shows that GHRP‑6 does raise GH, but newer non‑peptide drugs can do it even stronger.